In This Article:
-
Net Sales: SEK137 million, down 2.5% year-on-year.
-
Organic Growth: Down 3.5%, offset by favorable currency of 1.1%.
-
Adjusted Gross Profit: Approximately SEK60 million, with a gross margin improvement of 0.9 percentage points.
-
Adjusted EBIT: SEK9.9 million, up 13.8%.
-
Adjusted Operating Margin: 7.2%, improved by 1 percentage point.
-
Cash Flow from Operating Activities: Improved significantly, up 306% compared to last year.
-
Number of Instruments Sold: 883 units, roughly 10% below last year.
-
3-Part Unit Sales: Up 14% year-on-year.
-
5-Part Unit Sales: Down 65% year-on-year.
-
OEM Growth: Up 12% year-on-year, with a 118% growth from Q1 2021 to present.
-
Adjusted Operating Expenses: Decreased by 5% compared to last year.
-
Liquidity: Stable cash position of SEK35 million with SEK47 million in unused credit facilities.
Release Date: July 22, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Boule Diagnostics AB (STU:8BD) has a strong foundation of skilled personnel committed to delivering quality medical equipment and services.
-
The company has unique capabilities in developing and manufacturing the entire hematology lifecycle, from analyses to aftermarket service support.
-
Boule Diagnostics AB (STU:8BD) has a strong brand recognition and loyal customer base due to its pioneering history in hematology.
-
The company has made strategic adjustments to improve cost efficiency, including an organizational restructure resulting in SEK8 million in annual savings.
-
Boule Diagnostics AB (STU:8BD) has achieved significant milestones in its portfolio strategy, including the inauguration of a new reagent manufacturing plant in India.
Negative Points
-
Net sales for Q2 2024 decreased by 2.5% year-on-year, with organic growth down 3.5%.
-
The company faced challenges in the Latam and Asia Pacific regions due to competition from low-cost Chinese manufacturers.
-
Hematology sales in Q2 2024 were soft, with a 10% decrease in the number of instruments sold compared to the previous year.
-
The operating margin was impacted by SEK8.5 million in one-time restructuring expenses and tax penalties.
-
The company is facing a competitive and decentralized hematology market, necessitating improvements in processes and operating efficiency.
Q & A Highlights
Q: Can you elaborate on the focus areas you've defined and whether you need to invest in building an organization to implement your action plan? A: We don't expect to build a new organization for strategic growth. Our focus is on expanding veterinary care by building a stronger distributor network. We have the commercial organization to support this but need to invest more effort in developing that network. Gradual improvements from these efforts are expected.